Codiak Biosciences Stock News

Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences

Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thorou

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s

– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc

Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials.  In an

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s

– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK ), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy , in the American Association for the Advancement of Science''s journal, Science Advances . exoASO™-STAT6 is a novel, engineered exosome precision medicine candidate in development for the treatment of macrophage-rich tumors. This publication details the findings from the preclinical development program and highlights the ability of exoASO-STAT6 to selectively target tumor associated immune-suppressive macrophages (TAMs) and precisely disrupt STAT6 signaling to generate impressive monotherapy anti-tumor activity in cancer models. "Based on our preclinical observations, we believe exoASO-STAT6 is the first macrophage targeting candidate to show single agent anti-tumor activity of this magnitude, thus offering the potential to overcome significant barriers to prior drug development efforts aimed at transcription factors," said Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, Codiak. "This publication describes the unique attributes and anti-tumor activity of exoASO-STAT6 in several preclinical cancer models, including colorectal and hepatocellular carcinomas, the latter of which we intend to be the focus of our initial clinical investigations of this candidate." TAMs promote tumor growth by exhibiting an immune suppressive M2 phenotype.

Kaival Brands Innovations (KAVL) +20%. Codiak BioSciences (CDAK) +16%

Stocks Analysis by Zacks Investment Research covering: . Read Zacks Investment Research''s latest article on Investing.com

Codiak BioSciences, Inc. (CDAK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ne